November 04, 2021
In this interview, Michael Schweizer, MD, highlights a study of olaparib plus bipolar androgen therapy in patients with metastatic castration-resistant prostate cancer.
October 18, 2021
Alicia Morgans, MD, MPH, discusses a health economics analysis that assessed the clinical and cost impact of cabazitaxel (Jevtana) as a third-line treatment for patients with metastatic castration-resistant prostate cancer.
October 15, 2021
Scott T. Tagawa, MD, discusses a study of treatment patterns and overall survival in metastatic castration-sensitive prostate cancer between 2006 and 2019.
September 27, 2021
“The activity that we saw with the combination was very promising and…it justifies additional clinical trials to determine whether or not this could have a place in terms of our standard treatment options for patients,” says Michael Schweizer, MD.
September 21, 2021
Combining avelumab with standard neoadjuvant chemotherapy induced pathological complete responses in over half of patients with nonmetastatic muscle-invasive bladder cancer.
September 20, 2021
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.
Patients had received at least 1 novel hormonal agent and had non-progressive disease after subsequent treatment with taxane-based therapy.
September 19, 2021
"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.
There was limited clinical activity with the combination in patients with HRD-negative tumors.
Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.
